Aims: Neuromyelitis optica spectrum disorder (NMOSD) is an inflammatory autoimmune disease of the central nervous system. Increasing evidence indicates that NMOSD is a Th2-and Th17-dominant disease. IL-25, IL-31, and IL-33 are three newly found Th2-related cytokines, and their roles in the pathogenesis of NMOSD have not been studied. This study aimed to measure the serum levels of in patients with NMOSD and evaluate their clinical implications.
| INTRODUCTION
Neuromyelitis optica spectrum disorder (NMOSD) is an inflammatory autoimmune disease of the central nervous system (CNS). It is classically characterized by recurrent optic neuritis and transverse myelitis. It also includes anti-aquaporin-4 (AQP4)-IgG-seropositive patients with first-attack transverse myelitis, optic neuritis, or some brainstem and encephalitic presentations. 2, 3 T and B cells and various cytokines have been related to the pathogenesis of NMOSD. 4 Studies show that Th17-and Th2-associated cytokines are upregulated in the cerebrospinal fluid or serum of patients with NMOSD. 4 Therefore, based on current evidence, it is regarded that NMOSD expresses Th17 and Th2 axes in the development of the disease, whereas MS is primarily a Th1-dominant disease. 5 IL-17A and IL-6 are two cytokines of the Th17 axis. It is widely accepted that IL-17A
and IL-6 play pivotal roles in the development of NMOSD lesions. 5, 6 IL-25, IL-31 and IL-33 are newly discovered Th2-related cytokines. [7] [8] [9] [10] They have been proven to be involved in the
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immunopathology of disorders, including asthma, fulminant hepatitis, atopic dermatitis, Inflammatory Bowel Disease (IBD), and arthritis. [8] [9] [10] However, their roles in NMOSD have not been studied.
Therefore, in this study, we had the following aims: (i) to learn the serum levels of IL-25, IL-31, and IL-33 in patients with NMOSD compared to healthy controls (HC); (ii) to investigate the correlation between the serum levels of IL-25, IL-31, and IL-33 and the serum levels of IL-17A and IL-6 in patients with NMOSD; and (iii) to evaluate the clinical implications of serum IL-25, IL-31, and IL-33 levels in patients with NMOSD.
| METHODS

| Study population
The study was carried out at the Shanghai RenJi Hospital, which is a major teaching hospital of the Medical School of Shanghai Jiao Tong University. We recruited consecutive patients admitted to our clinical center from January 2015 to December 2016 with the diagnosis of NMOSD. In this study, the diagnoses of all the patients were reviewed, and only the patients who fulfilled the diagnostic criteria established by Wingerchuket al 11 in 2015 were included. We also chose healthy subjects who were matched well with the patients with NMOSD according to the age and sex of the controls.
The study was approved by the Ethics Committee of RenJi Hospital. Informed consent was obtained from all the included patients and healthy controls.
| Clinical data collection
The clinical, laboratory, and radiology records of all the included patients were retrospectively reviewed. The clinical information collected for the patients with NMOSD included age, sex, total disease duration, current disease duration, Expanded Disability Status Scale (EDSS) score, annualized relapse rate (ARR), serum status and titers of anti-AQP4 antibody, presentation of optic neuritis (ON), myelitis, longitudinally extensive transverse myelitis (LETM), characteristic brain lesions on MR images, and immunomodulatory drugs used at the time of sampling. Total disease duration is defined as the period from the time of the first attack to the time of sampling. Current disease duration refers to the period from the time of the current attack to the time of sampling. The patient was regarded as being in the acute phase of the attack if the current disease duration was less than 30 days. EDSS score was checked at the time of sampling. ARR is calculated using the time interval from the onset of the first attack to the time of sampling.
We define the relapse of NMOSD as a clinical exacerbation presenting with new or worsening symptoms accompanied with a change on the neurological examination that correlated with a new or enhancing MRI lesion. The interval should be at least 30 days since the previous relapse. 12 Anti-AQP4 and antimyelin-oligodendrocyte-glycoprotein
(MOG) antibodies were tested in all patients using a cell-based assay.
We defined severe ON as a visual function score of 5 or 6 on the 
| Blood sampling and the measurement of serum cytokines
Blood samples (3-5 mL) were drawn from the peripheral veins in a red- 
| Statistical analysis
Data analysis was performed using SPSS version 18.0 (SPSS Inc., Chicago, Ill., USA 
| RESULTS
| Clinical data of patients with NMOSD
A total of 48 patients were enrolled. The mean age was 44.0 years; the female to male ratio was 3:1. The median total disease duration was 348 days (IQR, 94.8-1715 days). The median current disease duration was 17.5 days (IQR, 9-32.8 days Eleven patients presented with an initial NMOSD attack.
At the time of sampling, 13 patients were drug-naïve, while 35 patients had already been treated with immunomodulatory drugs.
Twenty-three patients had used steroids only. Three patients had used immunosuppressants only. One patient had used IVIG only. Five patients had used both steroids and immunosuppressants. Three patients had used both steroids and IVIG.
| Serum levels of IL-25, IL-31, and IL-33 in patients with NMOSD
The mean serum levels of IL-25 and IL-31 were significantly higher in patients with NMOSD compared to HC (IL-25: 29.8 ± 1.5 pg/ mL vs 21.2 ± 1.3 pg/mL, P < 0.001; IL-31: 107 ± 5.4 pg/mL vs 74.2 ± 5.3 pg/mL, P < 0.001).
The median serum levels of IL-33 were also significantly higher and patients who were drug-naïve (n = 13). No significant difference was found between the two groups.
The serum levels of IL-25, IL-31, and IL-33 had no association with EDSS scores, total disease duration, or current disease duration. There was also no significant correlation between the level of cytokines and anti-AQP4 antibody titers.
As the cytokine levels in the acute phase can better represent the inflammatory status of the patients, only patients in the acute phase were included in the analysis of the correlation with ARR. Among the 32 patients in the acute phase, only the serum level of IL-33 was positively correlated with ARR (r = 0.364,P = 0.04; Figure 2 ).
| DISCUSSION
To our knowledge, the present study was the first one to detect the The discovery of the anti-AQP4 antibody in 2004 has dramatically changed our understanding of the pathophysiology of NMOSD. 
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IL-25 has protective roles against worm or bacterial infection; it might also participate in intestinal inflammation. IL-25 has been proven to be a pathogenic factor during allergic diseases (such as asthma and atopic dermatitis) due to its induction of Th2 cytokines. 7, 8 We found that the serum level of IL-25 was increased in patients with NMOSD.
Thus, we hypothesized that IL-25 might play a role in the pathogenesis of NMOSD by promoting the production of autoantibodies, such as the anti-AQP4 antibody.
IL-31 belongs to the family of IL-6 cytokines, which also includes IL-6, IL-11, and IL-27. 17 IL-31 is mainly produced by CD4 + T cells, particularly activated Th2 cells. 18 The IL-31 receptor complex has been found to be expressed by various cells, including dorsal root ganglia, activated monocytes, macrophages, basophils, eosinophils, and keratinocytes. 19 Recent studies reported that patients with inflammatory bowel disease, asthma, allergic rhinitis, and atopic dermatitis had increased IL-31 serum levels. 9 Moreover, the serum levels IL-31 had been correlated with disease activity in some of the above-mentioned diseases. 9 In the current study, we found an increased serum level of IL-31 in patients with NMOSD. We also noted a positive correlation between serum level of IL-31 and IL-17A, which is identified as a critical cytokine in the pathogenesis of NMOSD. Th17-and Th1-coordinated inflammation, including neutrophil and
The serum level of IL-33 in the acute phase was positively correlated with annualized relapse rate (ARR) in patients with neuromyelitis optica spectrum disorders (NMOSD) (r = 0.364, P = 0.04) antiviral T-cell responses. The effects of IL-33 in health and disease are highly tissue-specific and are influenced by the microenvironment. 9 Recent studies proved that the IL-33:ST2 axis was involved in the immunopathology of diseases, including atopic dermatitis, asthma, inflammatory bowel disease, and arthritis. [24] [25] [26] As NMOSD is regarded as a Th17-and Th2-dominant disease, we hypothesized that IL-33 might also be involved in the pathogenesis of the disease by promoting Th17-and Th2-related immune responses. The results of our study partially verified this hypothesis. In the current study, we revealed a higher serum level of IL-33 in patients with NMOSD compared to HC; a higher level of serum IL-33 may suggest the presence of typical brain lesions of NMOSD; moreover, a higher serum level of IL-33 during an acute phase was related to more past attacks, which may imply a higher disease activity in patients with NMOSD. Therefore, further study is warranted to disclose a detailed mechanism of IL-33 in the immunopathology of NMOSD. In addition, as predictors of the relapse of NMOSD are currently lacking, IL-33 might be a promising candidate.
As far as we know, this is the first study to reveal the possible role of the three newly discovered Th2-related cytokines in the pathogenesis of NMOSD. However, there are several limitations. One limitation in this study is the relatively small number of patients included and the lack of follow-up; therefore, large-scale studies should be conducted with longer periods of follow-up. Second, we only detected the serum level of the cytokines; it would be much better if we could detect the serum and CSF levels simultaneously. Third, we did not compare the serum levels of the cytokines of the same patient before and after immunomodulatory treatment and during the different stages of the disease, which could be different. Finally, underlying mechanisms of the three cytokines in NMOSD pathogenesis should be further studied. Furthermore, it might not be appropriate that MOG-IgG positive patients were included in the current study as accumulating evidence suggests that anti-MOG-related disorders might be their own disease entity. [27] [28] [29] However, according to the 2015 diagnostic criteria of NMOSD, MOG-IgG is not explicitly mentioned as an exclusion criterion; therefore, we still included patients with MOG-IgG positive who met the 2015 criteria in the current study.
| CONCLUSION
In conclusion, we found higher serum levels of IL-25, IL-31, and IL-33 in patients with NMOSD compared to HC. A higher level of serum IL-33 may suggest the presence of typical brain lesions of NMOSD; furthermore, a higher serum level of IL-33 during an acute phase may imply a higher disease activity in patients with NMOSD. However, further studies are required to investigate the underlying mechanisms of the three cytokines and the immunopathology of NMOSD.
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